Brief: Barinthus Bio Provides A Financial Update And Announces Anticipated 2024 Corporate Milestones
05/01/2024 22:17
Jan 5 (Reuters) - Barinthus Biotherapeutics PLC
2ABy.F :
* BARINTHUS BIO PROVIDES A FINANCIAL UPDATE AND ANNOUNCES
ANTICIPATED 2024 CORPORATE MILESTONES
* BARINTHUS BIOTHERAPEUTICS PLC - CASH RUNWAY ANTICIPATED TO
BE
EXTENDED FROM Q2 2025 TO Q4 2025
* BARINTHUS BIOTHERAPEUTICS PLC - DATA FROM MULTIPLE PHASE 1
AND 2
CLINICAL TRIALS EXPECTED IN 2024
* BARINTHUS BIOTHERAPEUTICS PLC - CASH AND CASH EQUIVALENTS
EXPECTED TO BE $142 MILLION AS OF DECEMBER 31, 2023.
Source text for Eikon: ID:nGNX4KlGL3
Further company coverage: 2ABy.F
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing